|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-5-9
|
|
pubmed:abstractText |
Hospitalizations for worsening heart failure due to fluid overload (congestion) are common. Agents that treat congestion without causing electrolyte abnormalities or worsening renal function are needed. Tolvaptan is an oral vasopressin (V 2 ) antagonist that decreases body weight and increases urine volume without inducing renal dysfunction or hypokalemia. The Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is evaluating mortality, morbidity, and patient-assessed global clinical status in patients treated with tolvaptan compared with standard care.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1071-9164
|
|
pubmed:author |
pubmed-author:BurnettJohn CJC,
pubmed-author:DemetsDavidD,
pubmed-author:GheorghiadeMihaiM,
pubmed-author:GrinfeldLilianaL,
pubmed-author:KonstamMarvin AMA,
pubmed-author:MaggioniAldoA,
pubmed-author:OrlandiCesareC,
pubmed-author:SwedbergKarlK,
pubmed-author:UdelsonJames EJE,
pubmed-author:ZannadFaiezF,
pubmed-author:ZimmerChristopherC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
260-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15880334-Benzazepines,
pubmed-meshheading:15880334-Body Weight,
pubmed-meshheading:15880334-Double-Blind Method,
pubmed-meshheading:15880334-Follow-Up Studies,
pubmed-meshheading:15880334-Heart Failure,
pubmed-meshheading:15880334-Hospitalization,
pubmed-meshheading:15880334-Humans,
pubmed-meshheading:15880334-Hypokalemia,
pubmed-meshheading:15880334-Placebos,
pubmed-meshheading:15880334-Quality of Life,
pubmed-meshheading:15880334-Receptors, Vasopressin,
pubmed-meshheading:15880334-Research Design,
pubmed-meshheading:15880334-Stroke Volume,
pubmed-meshheading:15880334-Survival Rate,
pubmed-meshheading:15880334-Treatment Outcome,
pubmed-meshheading:15880334-Urination,
pubmed-meshheading:15880334-Ventricular Dysfunction, Left
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
|
|
pubmed:affiliation |
Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
